Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2010

Open Access 01-12-2010 | Research article

The potential interaction between clopidogrel and proton pump inhibitors: a systematic review

Authors: Joao Paulo de Aquino Lima, James M Brophy

Published in: BMC Medicine | Issue 1/2010

Login to get access

Abstract

Background

Recently, several publications have investigated a possible drug interaction between clopidogrel and proton pump inhibitors (PPIs), and regulatory agencies have issued warnings despite discordant study results. In an attempt to clarify the situation, we performed a systematic review with a critical analysis of study methodologies to determine whether varying study quality (that is, bias) could explain the discordant results.

Methods

A systematic review of all studies reporting clinical outcomes was performed using an electronic literature search of the MEDLINE and EMBASE databases, abstracts from the major cardiology conferences and a hand-search of bibliographies from identified articles. Each study was evaluated for its risk of bias according to a prespecified quality measure scale.

Results

A total of 18 studies were identified. Ten of 13 studies judged to be of low scientific quality reported a statistically positive interaction between clopidogrel and the general class of PPIs, and each concluded this was likely a clinically meaningful effect. None of the five studies judged to be of moderate or high quality reported a statistically significant association. Multiple sources of heterogeneity (that is, different populations, outcomes assessed, drug exposure methods and study quality) prevented a formal quantitative analysis of all studies. An increased risk of bias was observed in the positive studies, resulting in an inverse correlation between study quality and a reported statistically positive interaction (10/13 versus 0/5; P = p = 0.007). There was also no clinical evidence for a positive interaction according to specific PPIs.

Conclusion

The observed association between clopidogrel and PPIs is found uniquely in studies judged to be of low quality and with an increased risk of bias. High-quality evidence supporting a clinically significant clopidogrel/PPI interaction is presently lacking.
Appendix
Available only for authorised users
Literature
1.
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001, 345: 494-502. 10.1056/NEJMoa010746.CrossRef
2.
Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, Defreyn G, Maffrand JP: Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992, 44: 527-532. 10.1016/0006-2952(92)90445-O.CrossRef
3.
Steinhubl SR: Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines. Circulation. 2010, 121: 481-483. 10.1161/CIR.0b013e3181d1e0e1.CrossRef
4.
Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003, 107: 32-37. 10.1161/01.CIR.0000047060.60595.CC.CrossRef
5.
Martin PT, Denman R: Atorvastatin-clopidogrel interaction. Circulation. 2003, 107: e223-10.1161/01.CIR.0000077528.26542.DC.CrossRef
6.
Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD: Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation. 2004, 109: 1335-1338. 10.1161/01.CIR.0000124581.18191.15.CrossRef
7.
Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, Brissy O, Morange PE, Alessi MC, Bonnet JL: Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009, 54: 1149-1153. 10.1016/j.jacc.2009.05.050.CrossRef
8.
Gilard M, Arnaud B, Cornily JC, Le GG, Lacut K, Le CG, Mansourati J, Mottier D, Abgrall JF, Boschat J: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008, 51: 256-260. 10.1016/j.jacc.2007.06.064.CrossRef
9.
Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B: Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009, 157: 148-10.1016/j.ahj.2009.03.015. e1-e5
10.
Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ: Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008, 48: 475-484. 10.1177/0091270008315310.CrossRef
11.
Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009, 301: 937-944. 10.1001/jama.2009.261.CrossRef
12.
Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009, 180: 713-718.CrossRef
13.
14.
15.
Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008, 103: 2890-2907. 10.1111/j.1572-0241.2008.02216.x.CrossRef
16.
Chow CK, Moayyedi P, Devereaux PJ: Is it safe to use a proton pump inhibitor with clopidogrel?. Pol Arch Med Wewn. 2009, 119: 564-568.
17.
Juhasz M, Herszenyi L, Tulassay Z: Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist. Digestion. 2010, 81: 10-15. 10.1159/000243717.CrossRef
18.
Juurlink DN: Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation. 2009, 120: 2310-2312. 10.1161/CIRCULATIONAHA.109.907295.CrossRef
19.
Norgard NB, Mathews KD, Wall GC: Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009, 43: 1266-1274. 10.1345/aph.1M051.CrossRef
20.
Zarowitz BJ: Clopidogrel: with or without a proton pump inhibitor?. Geriatr Nurs. 2009, 30: 188-192. 10.1016/j.gerinurse.2009.03.001.CrossRef
21.
Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007, 370: 1453-1457. 10.1016/S0140-6736(07)61602-X.CrossRef
22.
Cox E, Martin BC, Van ST, Garbe E, Siebert U, Johnson ML: Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value Health. 2009
23.
Aubert RE, Epstein RS, Teagarden JR, Xia F, Yao J, Desta Z, Skaar T, Flockhart DA: Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study. Circulation. 2008, 118: S815.
24.
Banerjee S, Varghese C, Weideman R, Weideman M, Little BB: Proton pump inhibitors increase the risk of major adverse cardiovascular events in post-PCI patients who are on clopidogrel (Abstract P653). Eur Heart J. 2009, 30 (Suppl): 92.
25.
Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP: Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010.
26.
Dunn SP, Macaulay TE, Brennan DM, Campbell CL, Charnigo RJ, Smyth SS, Berger PB, Steinhubl SR, Topol EJ: Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial. Circulation. 2008, 118: S815-(Abstract 3999)
27.
Gaspar A, Ribeiro S, Naibas S, et al: Proton pump inhibitors in patients treated with aspirin and clopidogrel (Abstract P2679). Eur Heart J. 2009, 30 (Suppl): 444.
28.
Gupta E, Bansal D, Sotos J, Olden K: Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 2010, 55: 1964-1968. 10.1007/s10620-009-0960-8.CrossRef
29.
Huang CC, Chen YC, Leu HB, Chen TJ, Lin SJ, Chan WL, Chen JW: Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol. 2010, 105: 1705-1709. 10.1016/j.amjcard.2010.01.348.CrossRef
30.
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009, 374: 989-997.CrossRef
31.
Pezalla E, Day D, Pulliadath I: Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008, 52: 1038-1039. 10.1016/j.jacc.2008.05.053.CrossRef
32.
Ramirez JF, Selzer F, Chakaprani R, et al: Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry. J Am Coll Cardiol. 2009, 53 (Suppl 1): A27.
33.
Rassen JA, Choudhry NK, Avorn J, Schneeweiss S: Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009, 120: 2322-2329. 10.1161/CIRCULATIONAHA.109.873497.CrossRef
34.
Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, Daugherty JR, Kaltenbach LA, Stein CM: Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010, 152: 337-345.CrossRef
35.
Sarafoff N, Sibbing D, Sonntag U, Schulz S, Schoemig A, Kastrati A: Higher stent thrombosis rate after coronary stenting in patients on dual antiplatelet treatment and concomitant treatment with proton pump inhibitors (abstr). Eur Heart J. 2009, 30 (Suppl): 150.
36.
Stockl KM, Le L, Zakharyan A, Harada AS, Solow BK, Addiego JE, Ramsey S: Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010, 170: 704-710. 10.1001/archinternmed.2010.34.CrossRef
37.
Tsiaousis GZ, Zairis MN, Patsourakos N, et al: Oral proton pump inhibitors and their impact on the effectiveness of dual anti-platelet therapy during the first year after elective coronary stenting (abstr). J Am Coll Cardiol. 2009, 53 (Suppl A): A335.
38.
Charlot M, Ahlehoff O, Norgaard ML, Jorgensen CH, Sorensen R, Abildstrom SZ, Hansen PR, Madsen JK, Kober L, Torp-Pedersen C, Gislason G: Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010, 153: 378-386.CrossRef
39.
Allen MJ, McLean-Veysey P: Interaction between clopidogrel and proton pump inhibitors. CMAJ. 2009, 180: 1228-1229.CrossRef
40.
Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002, 288: 2411-2420. 10.1001/jama.288.19.2411.CrossRef
41.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, CHARISMA Investigators: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006, 354: 1706-1717. 10.1056/NEJMoa060989.CrossRef
42.
Suissa S: Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008, 167: 492-499. 10.1093/aje/kwm324.CrossRef
43.
44.
Anonymous: Editorial: Are medical journals getting better-or worse?. Lancet. 2009, 374: 950.
45.
Metadata
Title
The potential interaction between clopidogrel and proton pump inhibitors: a systematic review
Authors
Joao Paulo de Aquino Lima
James M Brophy
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2010
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-8-81

Other articles of this Issue 1/2010

BMC Medicine 1/2010 Go to the issue

Research article

Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma

Research article

Surveys of current status in biomedical science grant review: funding organisations' and grant reviewers' perspectives

Research article

Does targeting manual therapy and/or exercise improve patient outcomes in nonspecific low back pain? A systematic review

Research article

Reporting methods in studies developing prognostic models in cancer: a review

Research article

The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A

Minireview

Advances in drug therapy for systemic lupus erythematosus